PFE vs JNJ
Pfizer Inc. vs Johnson & Johnson · Updated Mar 28, 2026
PFE — 9 winsJNJ — 14 wins
Price Performance
PFE +7.26%JNJ +46.88%
Performance
| PFE | JNJ | |
|---|---|---|
| 1 Month | -0.17% | -1.52% |
| 3 Months | +8.09% | +15.40% |
| 6 Months | +14.64% | +34.91% |
| YTD | +8.65% | +15.86% |
| 1 Year | +7.32% | +48.27% |
| 3 Year | -47.28% | +45.35% |
| 5 Year | -26.60% | +67.20% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | +7.4% | -6.4% | -10.8% | -43.8% | -9.4% | +60.4% | -0.8% | -9.4% | +19.8% | +9.8% | +1.6% | +3.0% |
| JNJ | +16.0% | +43.7% | -9.6% | -12.0% | +3.0% | +9.3% | +7.8% | +14.2% | -7.3% | +20.6% | +14.7% | -1.7% |
Valuation
| PFE | JNJ | |
|---|---|---|
| P/E Ratio | 19.89 | 21.72 |
| Forward P/E | 9.36 | 20.58 |
| PEG Ratio | — | 2.47 |
| P/S Ratio | 2.45 | 6.02 |
| P/B Ratio | 1.77 | 6.96 |
| EV/EBITDA | 13.09 | 14.78 |
Financials
| PFE | JNJ | |
|---|---|---|
| EPS (TTM) | $1.36 | $11.04 |
| Gross Margin | +69.97% | +67.56% |
| Operating Margin | -9.35% | +20.22% |
| Net Margin | -9.34% | +20.83% |
| ROE | +9.00% | +32.87% |
| ROA | +3.75% | +13.46% |
| Debt/Equity | 0.78 | 0.51 |
Growth
| PFE | JNJ | |
|---|---|---|
| Revenue Growth YoY | -1.16% | +9.08% |
| Revenue Growth QoQ | +5.42% | +2.38% |
| EPS Growth YoY | -514.29% | +48.23% |
| EPS Growth QoQ | -146.77% | -1.42% |
Technical
| PFE | JNJ | |
|---|---|---|
| RSI (14) | 47.28 | 49.94 |
| % From 20-Day SMA | +0.16% | -0.41% |
| % From 50-Day SMA | +0.93% | +1.21% |
| % From 200-Day SMA | +6.58% | +21.93% |
| % From 52-Week High | -3.17% | -4.74% |
| % From 52-Week Low | +29.36% | +69.46% |
Analyst Ratings
PFE
Hold(12 analysts)
Strong SellHoldStrong Buy
Price Target
$27.50
+2.36% upside
JNJ
Buy(37 analysts)
Strong SellHoldStrong Buy
Price Target
$228.73
-2.73% upside
Overview
| PFE | JNJ | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $153.44B | $567.22B |
| Shares Outstanding | 5.69B | 2.41B |
| Avg Volume (10D) | 41.21M | 7.97M |
| Dividend Yield | 6.37% | 2.21% |
Frequently Asked Questions
Is PFE or JNJ a better buy right now?
Based on 23 comparable metrics, JNJ leads in 14 categories while PFE leads in 9. JNJ has a consensus analyst rating with 37 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, PFE or JNJ?
Over the past year, PFE returned +7.32% compared to JNJ's +48.27%. In the short term (1 month), PFE returned -0.17% vs JNJ's -1.52%.
Is PFE or JNJ more expensive?
PFE trades at a P/E of 19.89 compared to JNJ's 21.72. On a price-to-sales basis, PFE trades at 2.45x vs JNJ's 6.02x. Forward P/E: PFE at 9.36 vs JNJ at 20.58.
Which stock has higher growth, PFE or JNJ?
PFE's revenue grew -1.16% year-over-year compared to JNJ's +9.08%. EPS growth: PFE at -514.29% vs JNJ at +48.23%.
Do PFE and JNJ pay dividends?
PFE pays a dividend with a yield of 6.37%. JNJ pays a dividend with a yield of 2.21%.
Which stock do analysts prefer, PFE or JNJ?
PFE has 12 analysts with a target price of $27.50 (+2.36% upside). JNJ has 37 analysts with a target of $228.73 (-2.73% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.